Reprogramming to resist.

Kelly, Kathleen, and Steven P Balk. 2017. “Reprogramming to Resist.”. Science (New York, N.Y.) 355 (6320): 29-30.

Last updated on 06/11/2025
PubMed

Recent Publications

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.
A carboxy-terminal ubiquitylation site regulates androgen receptor activity.
WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth.
Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer.

Secondary menu